Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura: Real-World Multicenter Data on Re-Administration and Plasma Exchange Free Treatment

Blood (2022) 140 (Supplement 1): 8503–8504.

https://doi.org/10.1182/blood-2022-158549

Published: 2022

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome: A Large Series from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Blood (2019) 134 (Supplement_1): 2053.

https://doi.org/10.1182/blood-2019-129949

Published: 2019

Journal Articles

Underdiagnosed Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome(VOD/SOS) As a Major Cause of Multi-Organ Failure in Acute Leukemia Transplant Patients: An Analysis from the EBMT Acute Leukemia Working Party

Blood (2019) 134 (Supplement_1): 4483.

https://doi.org/10.1182/blood-2019-124065

Published: 2019

Journal Articles

Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey

Maximilian Merz, Isabelle Vande Broek, MD PhD, Manuel Pérez, Dr., Brigitte Kolb, MD, Argiris Symeonidis, MD PhD, Emmanouil Nikolousis, Athanasios Zomas, Francisco Gonzalez, Lenka Kellermann, BS, MBA, Hartmut Goldschmidt

Blood (2019) 134 (Supplement_1): 3115.

https://doi.org/10.1182/blood-2019-122706

Published: 2019

Journal Articles

Azacitidine Improves Outcome in Patients with MDS and AML with High Risk Cytogenetics - a Single Center Experience

Vidhya Murthy, MRCP,, Nilupulee Kapuge, Charalampos Kartsios, MD, Joanne Ewing, PhD BMBS, BSc, FRPATH,, Evgenia Xenou, Maria Kaparou, Elmoamly Shereef, Emmanouil Nikolousis

Blood (2018) 132 (Supplement 1): 5529.

https://doi.org/10.1182/blood-2018-99-109774

Published: 2018

Journal Articles

Remission Status at Transplantation and Treatment History Determine the Survival Chances of Patients after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia Who Had Received Pre-Treatment with Idelalisib: A Report from the EBMT Chronic Malignancies Working Party

Blood (2017) 130 (Supplement 1): 4576.

https://doi.org/10.1182/blood.V130.Suppl_1.4576.4576

Published: 2017

Journal Articles

Efficacy and Safety of Melphalan 140mg/m 2 Conditioned Autologous Stem Cell Transplantation in Elderly Pre-Dialysis and Dialysis Patients with Multiple Myeloma

Hatem Ali, MBBS, Baharani Jyoti, MBBS, FRCP, Shankaranarayana Paneesha, MD, Richard Lovell, Alex George Kanellopoulos, MD, Evgenia Xenou, MD, Iman Qureshi, MBBS, MRCP, Lorna Cain, Maria Kaparou, David John Sutton, MBBChir, MRCP, BSc, Rebecca Pryor, MB, MRCP, Emmanouil Nikolousis, PhDMBBS,FRCPath,MBA, Bhuvan Kishore, MBBS, MRCP, FRCPath

Blood (2016) 128 (22): 5822.

https://doi.org/10.1182/blood.V128.22.5822.5822

Published: 2016

Journal Articles

Single Centre Experience of Managing Patients with Double Hit Lymphoma

Shankaranarayana Paneesha, MD FRCP, FRCPath, Iman Qureshi, MBBS, MRCP, Malahat Saeed, MBBS MRCP, Richard Lovell, Emmanouil Nikolousis, PhDMBBS,FRCPath,MBA, Bhuvan Kishore, MBBS, MRCP, FRCPath, Kathy Holder, Maria Kaparou

Blood (2016) 128 (22): 5868.

https://doi.org/10.1182/blood.V128.22.5868.5868

Published: 2016

Journal Articles

12-Month Full Donor Chimerism Is Associated with Low-Grade Acute Graft Versus Host Disease (aGVHD) and Predicts Superior Outcomes in Reduced Intensity (RIC) Alemtuzumab-Based Transplants for MDS and AML

Alex George Kanellopoulos, MD, Shankaranarayana Paneesha, MD, Evgenia Xenou, MD, Iman Qureshi, MBBS, MRCP, Dewi Tomos Eden, MRCP,MB,FRCPath, David John Sutton, MBBChir, MRCP, BSc, Rebecca Pryor, MB, MRCP, Lorna Cain, Carolina Arbuthnot, Richard Lovell, Anton Borg, MDFRCP,FRCPath, Katie Randall, MB, FRCPath, Kathy Holder, Julie Suhr, Lynda Baker, Lynn Ryan, Maria Kaparou, Bhuvan Kishore, MBBS, MRCP, FRCPath, Emmanouil Nikolousis, PhD MBBS, FRCPath, MBA

Blood (2016) 128 (22): 5764.

https://doi.org/10.1182/blood.V128.22.5764.5764

Published: 2016

Journal Articles

Colony Stimulating Factors (Pegfilgrastim or Lenograstim) Use in Patients with Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is Associated with Early Neutrophil Engraftment and Shorter Inpatient Stay with No Impact on Progression Free Survival (PFS) or Overall Survival (OS)

Georgina Mayer, Bhuvan Kishore, MBBS, FRCPATH, MRCP, Richard Lovell, Emmanouil Nikolousis, PhD, Shankaranarayana Paneesha, MD FRCP, FRCPath

Blood (2015) 126 (23): 5450.

https://doi.org/10.1182/blood.V126.23.5450.5450

Published: 2015

Journal Articles

A Retrospective Single Center Comparison of Cyclophosphamide Plus G-CSF Versus G-CSF Alone for Peripheral Blood Stem Cell (PBSC) Mobilisation Following First Line Therapy in Patients with Multiple Myeloma

Richard S Whitmill, MBCHB FRCPath, David J Lewis, David John Sutton, MBBChir, MRCP, BSc, Jahanzeb Khawaja, MB CHB MRCP, Georgina Mayer, MB CHB MRCP, Shankaranarayana Paneesha, MD, Emmanouil Nikolousis, PhD, Bhuvan Kishore, MBBS, FRCPATH, MRCP

Blood (2015) 126 (23): 1898.

https://doi.org/10.1182/blood.V126.23.1898.1898

Published: 2015

Journal Articles

Split Mixed Donor Chimerism Early after T-Cell Depleted Reduced Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation Predicts Survival

Francesca A M Kinsella, MBChB, PhD MRCP, Amy Gudger, MBBS, MRCP, Charlotte F Inman, PhD, Graham Mc Ilroy, MBChB, PhD, Sandeep Nagra, MD, Jane Nunnick, Dave Waldron, Kerry Wall, Mike Griffiths, Paul Moss, MDPhD, Charles Craddock, MDPhD, Emmanouil Nikolousis, PhD, Ram Malladi, MBBS, PhD MRCP

Blood (2014) 124 (21): 423.

https://doi.org/10.1182/blood.V124.21.423.423

Published: 2014

Journal Articles

CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT

Karl S Peggs, Eleni Tholouli, Ronjon Chakraverty, PhD, Emmanouil Nikolousis, PhD, Adrian Bloor, PhD FRCPath, Stephen Devereux, MD PhD FRCPath, Kim H. Orchard, PhD, Charles Crawley, Anne Parker, Stephen P Robinson, PhD, Frederick Chen, MDPhD, Gordon Cook, MD, Richard E Clark, MBBS MD, Kirsty Thomson, Matthew Cobb, Katy Newton, PhD, Simon Thomas, PhD, Paul Moss, PhD

Blood (2014) 124 (21): 1109.

https://doi.org/10.1182/blood.V124.21.1109.1109

Published: 2014

Journal Articles

Autologous Stem Cell Transplant Has a Role In Consolidating Chemotherapy Given At First Disease Progression In Multiple Myeloma Treated Exclusively With Novel Agents

Blood (2013) 122 (21): 5514.

https://doi.org/10.1182/blood.V122.21.5514.5514

Published: 2013

Journal Articles

Pre-Transplantation Assessment Of Mortality (PAM) Score Is a Poor Predictor For Survival In The Highest Risk Group When Used In T Cell Depleted Myeloablative Allogeneic Transplants

Bhuvan Kishore, Daniel Wiseman, MBChB, MRCP, Emmanouil Nikolousis, Richard Lovell, Donald Milligan, MD, Kathy Holder, Lynn Bratby, Vidhya Murthy, Shankaranarayana Paneesha

Blood (2013) 122 (21): 5553.

https://doi.org/10.1182/blood.V122.21.5553.5553

Published: 2013

Journal Articles

Utility of Blood Cultures in Febrile Patients in a BCSH Level 4 Centre

Sophie Lee, Kesavan Kandiah, Kate Holyhead, Sandar Aung, Neil Smith, Emmanouil Nikolousis, Shankaranarayana Paneesha

Blood (2011) 118 (21): 4779.

https://doi.org/10.1182/blood.V118.21.4779.4779

Published: 2011

Journal Articles

Reduced Intensity Allogeneic Tranplants Are Well Tolerated In Patients Over the Age of 60: Identification of Factors Predicting Overall Survival

Emmanouil Nikolousis, Sandeep Nagra, Janice Ward, Fiona L Dignan, MD, Bronwen E. Shaw, PhD, MRCP, FRCPath, Simon Littlewood, Jenny Byrne, MD, PhD, Maria Helena Gilleece, MD, FRCPath, MB, BSc, FRCP, Eleni Tholouli, Fiona Clark, Mark Cook, Premini Mahendra, MD, Gordon Cook, MD, John Yin, MD, Nigel H. Russell, MD, Charles Craddock

Blood (2010) 116 (21): 2361.

https://doi.org/10.1182/blood.V116.21.2361.2361

Published: 2010

Journal Articles

Pretransplant Characteristics Could Predict Full Donor Chimerism on Day +90 and Day +180 and Outcomes in Reduced Intensity Alemtuzumab Conditioning Allogeneic Transplantation Can Be Influenced by Chimeric Status

Emmanouil Nikolousis, Charles F. Craddock, BM, MRCP, MRCPath, Shankaranarayana Paneesha, MD, Sudhir Tauro, Prem Mahendra, II, Mark Cook, Fiona Clark, Richard Lovell, Sridhar Chaganti, Donald Milligan, MD, MBChB, Dominique Mcmullan, Mike Griffiths, Stephen P Robinson, MD

Blood (2008) 112 (11): 4409.

https://doi.org/10.1182/blood.V112.11.4409.4409

Published: 2008

Journal Articles

Transplant Outcome Is Not Affected by Body Mass Index (BMI) in Patients with Haematological Malignancies.

Emmanouil Nikolousis, Shankaranarayana Paneesha, MD MRCP MRCPath, Kathy Holder, Lynn Bratby, Srinivas Pillai, Richard Lovell, Don Milligan, MD FRCP FRCPath

Blood (2007) 110 (11): 1991.

https://doi.org/10.1182/blood.V110.11.1991.1991

Published: 2007

NARROW

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura: Real-World Multicenter Data on Re-Administration and Plasma Exchange Free Treatment

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome: A Large Series from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Underdiagnosed Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome(VOD/SOS) As a Major Cause of Multi-Organ Failure in Acute Leukemia Transplant Patients: An Analysis from the EBMT Acute Leukemia Working Party

Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey

Azacitidine Improves Outcome in Patients with MDS and AML with High Risk Cytogenetics - a Single Center Experience

Remission Status at Transplantation and Treatment History Determine the Survival Chances of Patients after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia Who Had Received Pre-Treatment with Idelalisib: A Report from the EBMT Chronic Malignancies Working Party

Efficacy and Safety of Melphalan 140mg/m 2 Conditioned Autologous Stem Cell Transplantation in Elderly Pre-Dialysis and Dialysis Patients with Multiple Myeloma

Single Centre Experience of Managing Patients with Double Hit Lymphoma

12-Month Full Donor Chimerism Is Associated with Low-Grade Acute Graft Versus Host Disease (aGVHD) and Predicts Superior Outcomes in Reduced Intensity (RIC) Alemtuzumab-Based Transplants for MDS and AML

A Retrospective Single Center Comparison of Cyclophosphamide Plus G-CSF Versus G-CSF Alone for Peripheral Blood Stem Cell (PBSC) Mobilisation Following First Line Therapy in Patients with Multiple Myeloma

Split Mixed Donor Chimerism Early after T-Cell Depleted Reduced Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation Predicts Survival

CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT

Autologous Stem Cell Transplant Has a Role In Consolidating Chemotherapy Given At First Disease Progression In Multiple Myeloma Treated Exclusively With Novel Agents

Pre-Transplantation Assessment Of Mortality (PAM) Score Is a Poor Predictor For Survival In The Highest Risk Group When Used In T Cell Depleted Myeloablative Allogeneic Transplants

Utility of Blood Cultures in Febrile Patients in a BCSH Level 4 Centre

Reduced Intensity Allogeneic Tranplants Are Well Tolerated In Patients Over the Age of 60: Identification of Factors Predicting Overall Survival

Pretransplant Characteristics Could Predict Full Donor Chimerism on Day +90 and Day +180 and Outcomes in Reduced Intensity Alemtuzumab Conditioning Allogeneic Transplantation Can Be Influenced by Chimeric Status

Transplant Outcome Is Not Affected by Body Mass Index (BMI) in Patients with Haematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only